drugset / Trial / NCT00044044

A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia

NCT00044044

Phase 2 Completed 356 enrolled Sumitomo Pharma America, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of the drug SM-13496 compared to a placebo and to haloperidol in patients with schizophrenia.

Timeline

Start
2002-07
Primary completion
2003-05
Completion
2003-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Haloperidol Other / unclassified 10 mg
Subject Lurasidone Small molecule 20 mg
Subject Lurasidone Small molecule 40 mg
Subject Lurasidone Small molecule 80 mg

Indications